Medtronic Reports Results of Resolute Onyx DES in Onyx ONE Global Study for High-Bleeding Risk Patients with One-Month DAPT 

Shots:

• The Onyx ONE global study involves assessing of Resolute Onyx DES vs Biosensor International’s BioFreedom DCS in ~2000 high bleeding risk patients with one month of dual antiplatelet therapy (DAPT)
• The Onyx ONE global study results: met its 1EPs of cardiac death, MI & ST @1yr. showing non-inferiority to comparator stent; acute performance with device success rate (92.8% vs 89.7%); Low LTR (2.8% vs 4.0%); ST (1.3% vs 2.1%); rate of the composite adverse event endpoint @1yr. (7.5% vs 8.8%) including lower MI events (4.3% vs 6.8%)
• The Resolute Onyx drug-eluting stent is an advanced workhorse DES for coronary diseases, heals vessels with its BioLinx polymer and Continuous Sinusoid Technology (CST) and has received CE mark & FDA’s approval in Sept’2014 & Apr’2017 respectively

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Wearable Technology